Clemens Decristoforo

10.6k total citations · 3 hit papers
205 papers, 7.7k citations indexed

About

Clemens Decristoforo is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Epidemiology. According to data from OpenAlex, Clemens Decristoforo has authored 205 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Radiology, Nuclear Medicine and Imaging, 75 papers in Oncology and 71 papers in Epidemiology. Recurrent topics in Clemens Decristoforo's work include Radiopharmaceutical Chemistry and Applications (99 papers), Neuroendocrine Tumor Research Advances (60 papers) and Lung Cancer Research Studies (39 papers). Clemens Decristoforo is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (99 papers), Neuroendocrine Tumor Research Advances (60 papers) and Lung Cancer Research Studies (39 papers). Clemens Decristoforo collaborates with scholars based in Austria, Germany and Czechia. Clemens Decristoforo's co-authors include Irene Virgolini, Elisabeth von Guggenberg, Christian Uprimny, Michael Gabriel, Dorota Kendler, Stephen J. Mather, Miloš Petřík, Hubertus Haas, Georg Dobrozemsky and Reto Bale and has published in prestigious journals such as PLoS ONE, NeuroImage and Brain.

In The Last Decade

Clemens Decristoforo

199 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

2007 746 citations Michael Gabriel, Clemens Decristoforo et al. profile →
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA

2017 310 citations Irene Virgolini, Clemens Decristoforo et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour

2017 263 citations Clemens Decristoforo, Elisabeth von Guggenberg et al. European Journal of Nuclear Medicine and Molecular Imaging profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Clemens Decristoforo Austria	48	3.8k	3.0k	2.9k	1.8k	1.6k	205	7.7k
Thomas M. Behr Germany	45	2.7k 0.7×	1.5k 0.5×	1.5k 0.5×	651 0.4×	397 0.3×	128	5.3k
Patrick A. Burch United States	38	1.0k 0.3×	2.7k 0.9×	766 0.3×	4.3k 2.4×	176 0.1×	86	7.6k
Kurt R. Zinn United States	45	1.6k 0.4×	1.6k 0.6×	396 0.1×	1.1k 0.6×	238 0.2×	203	7.1k
Takayuki Sumida Japan	52	979 0.3×	1.1k 0.4×	887 0.3×	420 0.2×	192 0.1×	381	9.2k
Cameron J. Koch United States	48	1.6k 0.4×	1.6k 0.5×	677 0.2×	1.3k 0.8×	252 0.2×	151	8.6k
Peter Laverman Netherlands	41	2.3k 0.6×	1.3k 0.4×	621 0.2×	676 0.4×	123 0.1×	123	5.2k
Mathew L. Thakur United States	41	2.2k 0.6×	1.1k 0.4×	730 0.3×	999 0.6×	108 0.1×	227	6.0k
Johannes Wolff United States	44	286 0.1×	1.4k 0.5×	993 0.3×	1.2k 0.7×	1.7k 1.1×	231	7.5k
Susan J. Knox United States	46	2.3k 0.6×	2.3k 0.8×	345 0.1×	1.3k 0.7×	218 0.1×	171	7.2k
Udo S. Gaipl Germany	55	2.0k 0.5×	2.3k 0.8×	477 0.2×	1.1k 0.6×	128 0.1×	256	9.4k

Countries citing papers authored by Clemens Decristoforo

Since Specialization

Citations

This map shows the geographic impact of Clemens Decristoforo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clemens Decristoforo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clemens Decristoforo more than expected).

Fields of papers citing papers by Clemens Decristoforo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clemens Decristoforo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clemens Decristoforo. The network helps show where Clemens Decristoforo may publish in the future.

Co-authorship network of co-authors of Clemens Decristoforo

This figure shows the co-authorship network connecting the top 25 collaborators of Clemens Decristoforo. A scholar is included among the top collaborators of Clemens Decristoforo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clemens Decristoforo. Clemens Decristoforo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abt, Beate, et al.. (2025). FpnA, the Aspergillus fumigatus homolog of human ferroportin, mediates resistance to nickel, cobalt and gallium but does not function in iron homeostasis. Communications Biology. 8(1). 399–399. 1 indexed citations

Hermann, Martin, et al.. (2024). Comparison of Two Chelator Scaffolds as Basis for Cholecystokinin-2 Receptor Targeting Bimodal Imaging Probes. Pharmaceuticals. 17(12). 1569–1569.

Morath, Volker, Birgit Blechert, Dominik Summer, et al.. (2023). Molecular Design of ⁶⁸Ga- and ⁸⁹Zr-Labeled Anticalin Radioligands for PET-Imaging of PSMA-Positive Tumors. Molecular Pharmaceutics. 20(5). 2490–2501. 3 indexed citations

Janota, Barbara, Alicja Hubalewska‐Dydejczyk, Melpomeni Fani, et al.. (2023). Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics. 15(3). 885–885. 2 indexed citations

Decristoforo, Clemens, Oliver Neels, & Marianne Patt. (2021). Emerging Radionuclides in a Regulatory Framework for Medicinal Products – How Do They Fit?. Frontiers in Medicine. 8. 678452–678452. 15 indexed citations

Larkin, Annemarie, David A. Fitzpatrick, Kieran Walshe, et al.. (2021). Generation and characterisation of a semi-synthetic siderophore-immunogen conjugate and a derivative recombinant triacetylfusarinine C–specific monoclonal antibody with fungal diagnostic application. Analytical Biochemistry. 632. 114384–114384. 5 indexed citations

Misslinger, Matthias, et al.. (2021). Desferrioxamine B-Mediated Pre-Clinical In Vivo Imaging of Infection by the Mold Fungus Aspergillus fumigatus. Journal of Fungi. 7(9). 734–734. 12 indexed citations

Pfister, Joachim, Miloš Petřík, Barbara Matuszczak, et al.. (2021). Antifungal Siderophore Conjugates for Theranostic Applications in Invasive Pulmonary Aspergillosis Using Low-Molecular TAFC Scaffolds. Journal of Fungi. 7(7). 558–558. 19 indexed citations

Petřík, Miloš, Joachim Pfister, Matthias Misslinger, Clemens Decristoforo, & Hubertus Haas. (2020). Siderophore-Based Molecular Imaging of Fungal and Bacterial Infections—Current Status and Future Perspectives. Journal of Fungi. 6(2). 73–73. 34 indexed citations

10.

Viveiros, André, Benedikt Schaefer, Armin Finkenstedt, et al.. (2020). Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease. Liver International. 40(8). 1941–1951. 13 indexed citations

11.

Pfister, Joachim, et al.. (2020). Siderophore Scaffold as Carrier for Antifungal Peptides in Therapy of Aspergillus fumigatus Infections. Journal of Fungi. 6(4). 367–367. 13 indexed citations

12.

Summer, Dominik, Christine Rangger, Roland Haubner, et al.. (2018). DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. Journal of Nuclear Medicine. 60(7). 1010–1016. 49 indexed citations

13.

Schwarz, Sally W., et al.. (2018). Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible?. Journal of Nuclear Medicine. 60(2). 158–166. 17 indexed citations

14.

Petřík, Miloš, Chuangyan Zhai, Hubertus Haas, & Clemens Decristoforo. (2016). Siderophores for molecular imaging applications. Clinical and Translational Imaging. 5(1). 15–27. 98 indexed citations

15.

Summer, Dominik, Claudia Manzl, Christine Rangger, et al.. (2016). Targeting Gastrointestinal Stromal Tumor with ⁶⁸ Ga-Labeled Peptides: An In Vitro Study on Gastrointestinal Stromal Tumor-Cell Lines. Cancer Biotherapy and Radiopharmaceuticals. 31(8). 302–310. 12 indexed citations

16.

Gabriel, Michael, Clemens Decristoforo, Ewald Wöll, et al.. (2011). [ ^99m Tc]Demotensin VI: Biodistribution and Initial Clinical Results in Tumor Patients of a Pilot/Phase I Study. Cancer Biotherapy and Radiopharmaceuticals. 26(5). 557–563. 13 indexed citations

17.

Decristoforo, Clemens, Janette Carlsen, Marco Rupprich, et al.. (2008). 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression. European Journal of Nuclear Medicine and Molecular Imaging. 35(8). 1507–1515. 133 indexed citations

18.

Gabriel, Michael, Clemens Decristoforo, Θεοδοσία Μάινα, et al.. (2004). ^99m Tc-N ₄ -[Tyr ³ ]Octreotate Versus ^99m Tc-EDDA/HYNIC-[Tyr ³ ]Octreotide: An Intrapatient Comparison of Two Novel Technetium-99m Labeled Tracers for Somatostatin Receptor Scintigraphy. Cancer Biotherapy and Radiopharmaceuticals. 19(1). 73–79. 24 indexed citations

19.

Riccabona, G & Clemens Decristoforo. (2003). Peptide Targeted Imaging of Cancer. Cancer Biotherapy and Radiopharmaceuticals. 18(5). 675–687. 24 indexed citations

20.

Gabriel, Michael, et al.. (2002). Comparison of clinical valence of 99m Tc-HYNIC-TOC with 111 In-DTPA-Octreotide in oncological diagnostics of somatostatin-receptor-positive tumours. 41(6). 22–23. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact